October 21, 2016 9:19 AM ET


Company Overview of Ardea Biosciences, Inc.

Company Overview

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout and cancer in the United States. Its product candidates include Lesinurad (RDEA594), an inhibitor of the URAT1 kidney transporter, which is in Phase III clinical trials for the treatment of gout; BAY 86-9766 (RDEA119), a mitogen-activated ERK kinase (MEK) inhibitor that is in Phase II clinical trials for the treatment of cancer; and RDEA3170, an URAT1 kidney transporter inhibitor, which is in Phase I clinical trials for the treatment of gout. The company has a development and commercialization license agreement with Bayer Healthcare AG to develop...

4939 Directors Place

San Diego, CA 92121

United States

107 Employees





Key Executives for Ardea Biosciences, Inc.

President and Chief Operating Officer
Chief Financial Officer, Principal Accounting Officer and Senior Vice President of Finance & Operations
Age: 56
Senior Vice President of Regulatory Affairs & Development Operations
Age: 56
Senior Vice President of Pharmaceutical Sciences
Age: 52
Vice President of Preclinical Development
Compensation as of Fiscal Year 2016.

Ardea Biosciences, Inc. Key Developments

Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with Ardea Biosciences, Inc. for Lesinurad

On April 26, 2016, Ironwood Pharmaceuticals, Inc. and Ardea Biosciences, Inc. (“Ardea”), an indirect wholly owned subsidiary of AstraZeneca PLC, entered into a license agreement pursuant to which Ardea granted to Ironwood a license for the commercialization, and the development, manufacture and support of such commercialization, of products containing lesinurad as an active ingredient, including Zurampic, in the United States. Subject to the terms of the License Agreement, Ardea will conduct certain development activities on Ironwood’s behalf for (i) Zurampic (including the post-marketing requirement activities currently required by the Food and Drug Administration, for which Ironwood will reimburse Ardea up to $100 million over up to ten years), and (ii) a fixed dose combination product with lesinurad and allopurinol as active ingredients, for which Ironwood will reimburse Ardea up to specified limits. Ironwood is responsible for any additional development of the Products for commercialization in the United States and for commercialization of the Products in the United States. In addition, under the terms of the License Agreement, Ironwood will have the right of first negotiation and a right of last refusal with Ardea for the right to commercialize (and develop and manufacture for commercialization) products comprising verinurad as at least one of its active ingredients for the prevention or treatment of gout in the United States. Pursuant to the terms of the License Agreement, Ironwood will make an upfront payment of $100 million to Ardea and will pay a royalty to Ardea in the single digits as a percentage of net sales of the Products in the United States (such royalty rate to be dependent on the aggregate net sales of the Products). Ardea is also eligible to receive $15 million following approval of the new drug application for the fixed dose combination product with lesinurad and allopurinol as active ingredients, as well as up to an aggregate of $150 million in additional commercial milestone payments over the term of the License Agreement, contingent on the achievement of certain net sales milestones in the United States. Subject to customary termination provisions, the License Agreement will continue as long as royalties are payable by Ironwood with respect to a Product.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ardea Biosciences, Inc., please visit www.ardeabio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.